The Outcome of the Chemotherapy and Oncothermia for Far Advanced Adenocarcinoma of the Lung: Case Reports of Four Patients

Lee, Deuk Yong; Park, Joon Seok; Jung, Hae Chul; Byun, Eun Seol; Haam, Seok Jin; Lee, Sungsoo

doi:10.4236/alc.2015.41001

Cited by 7 publications

(4 citation statements)

References 13 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mEHT treatment has successful clinical records on lung cancer (267), and case reports of advanced and special cases support its application (268,269). When mEHT was applied to lung tumors simultaneously with intravenous ascorbic acid the plasma concentration of ascorbic acid was significantly increased, compared to intravenous ascorbic acid applied alone, or after mEHT.…”

Section: Breastmentioning

confidence: 97%

Quo Vadis Oncological Hyperthermia (2020)?

et al. 2020

View full text Add to dashboard Cite

Heating as a medical intervention in cancer treatment is an ancient approach, but effective deep heating techniques are lacking in modern practice. The use of electromagnetic interactions has enabled the development of more reliable localregional hyperthermia (LRHT) techniques whole-body hyperthermia (WBH) techniques. Contrary to the relatively simple physical-physiological concepts behind hyperthermia, its development was not steady, and it has gone through periods of failures and renewals with mixed views on the benefits of heating seen in the medical community over the decades. In this review we study in detail the various techniques currently available and describe challenges and trends of oncological hyperthermia from a new perspective. Our aim is to describe what we believe to be a new and effective approach to oncologic hyperthermia, and a change in the paradigm of dosing. Physiological limits restrict the application of WBH which has moved toward the mild temperature range, targeting immune support. LRHT does not have a temperature limit in the tumor (which can be burned out in extreme conditions) but a trend has started toward milder temperatures with immune-oriented goals, developing toward immune modulation, and especially toward tumor-specific immune reactions by which LRHT seeks to target the malignancy systemically. The emerging research of bystander and abscopal effects, in both laboratory investigations and clinical applications, has been intensified. Our present review summarizes the methods and results, and discusses the trends of hyperthermia in oncology.

show abstract

Section: Breastmentioning

confidence: 97%

Quo Vadis Oncological Hyperthermia (2020)?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Cancers 2023, 15, x FOR PEER REVIEW 14 of 28 Another massively present malignancy in the world is advanced non-small-cell lung cancer (NSCLC). Application of mEHT on advanced NSCLCs also has numerous case studies [63,[122][123][124][125][126] and trials [60,79,[127][128][129][130]. The comparison of the survival distributions shows similarities again, and the data pool remarkably differs from the propensity score data by mining in USA and EU databases [130], Figure 8.…”

Section: Comparison Of Survival Curvesmentioning

confidence: 99%

The Clinical Validation of Modulated Electro-Hyperthermia (mEHT)

Lee,

Lorant,

Grand

et al. 2023

Cancers

View full text Add to dashboard Cite

The mEHT method uses tissues’ thermal and bioelectromagnetic heterogeneity for the selective mechanisms. The success of the therapy for advanced, relapsed, and metastatic aggressive tumors can only be demonstrated by measuring survival time and quality of life (QoL). The complication is that mEHT-treated patients cannot be curatively treated any longer with “gold standards”, where the permanent progression of the disease, the refractory, relapsing situation, the organ failure, the worsening of blood counts, etc., block them. Collecting a cohort of these patients is frequently impossible. Only an intent-to-treat (ITT) patient group was available. Due to the above limitations, many studies have single-arm data collection. The Phase III trial of advanced cervix tumors subgrouping of HIV-negative and -positive patients showed the stable efficacy of mEHT in all patients’ subgroups. The single-arm represents lower-level evidence, which can be improved by comparing the survival data of various studies from different institutes. The Kaplan–Meier probability comparison had no significant differences, so pooled data were compared to other methods. Following this approach, we demonstrate the feasibility and superiority of mEHT in the cases of glioblastoma multiform, pancreas carcinomas, lung tumors, and colorectal tumors.

show abstract

“…It has long been used in clinical practice for various malignant diseases, with efficacy proven by the numerous documented case reports and clinical studies. There have been some published case reports [25][26][27][28][29][30] and studies [31][32][33], showing its efficacy for the treatment of NSCLC and even in small cell lung cancer (SCLC) [34]. mEHT is based on the modulated electric field effect, which works in synergy with heat [35].…”

Section: Introductionmentioning

confidence: 99%